Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

24.71 -0.48 (-1.89%)
Official Closing Price Updated: 4:15 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects. 
Via The Motley Fool
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Trust these two real estate stocks to be attractively priced and proven performers. 
Via The Motley Fool
This Is What Whales Are Betting On Moderna
Via Benzinga
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The futures for these two beaten-down stocks could be brighter than their recent pasts. 
Via The Motley Fool
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
Via ACCESSWIRE
Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years
Via Benzinga
Moderna to Present at Upcoming Investor Conferences in March 2024
Via ACCESSWIRE
Where Moderna Stands With Analysts
Via Benzinga
Why Moderna Stock Is Jumping Today
The biotech company surprised investors with a Q4 profit. 
Via The Motley Fool
Earnings Seasons Score Card: 4 Stock Superstars and 3 That Fell Short
Watch these companies, whose share prices have seen big swings higher or lower after they reported Q4 2023 earnings. 
Via InvestorPlace
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track... 
Via Benzinga
Moderna Stock Has 33% Upside, According to 1 Wall Street Analyst
A lot is riding on whether there will be demand for its new vaccines. 
Via The Motley Fool
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak... 
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
Peering Into Moderna's Recent Short Interest
Via Benzinga
Block To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
Moderna (MRNA) Q4 2023 Earnings Call Transcript
MRNA earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Posts Quarterly Profit Despite Lower Sales From COVID-19 Vaccine
Moderna reports Q4 2023 revenues of $2.81 billion from Spikevax (COVID-19 vaccine), exceeding expectations. 
Via Benzinga
Exposures COVID-19
Moderna’s Unexpected $217 Million Profit Marks A Surprising Q4 Achievement
Moderna Inc. showcased a resilient fourth-quarter performance for the fiscal year 2023, navigating through the challenges posed by the transition to an endemic market environment. 
Via Talk Markets
Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum
Market participants remain attentive to several factors shaping the day's trading landscape, including scheduled Fed speeches, weekly jobless claims data, and private-sector activity readings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report
The company unexpectedly came in with fourth-quarter earnings that beat projections. 
Via Investor's Business Daily
Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Moderna, Inc. (NASDAQ: MRNA) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 22, 2024. 
Via Benzinga
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024. 
Via Benzinga
Exposures COVID-19 Product Safety
Looming Layoffs? 3 Companies That May Be the Next to Drop the Axe.
Layoffs were a big theme in 2023. Unless the economy drastically picks up in 2024, they could happen this year in large numbers. 
Via InvestorPlace
Topics Economy Workforce
Exposures Economy Layoff
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
To Sell or Not to Sell: How to Handle the Inevitable Nvidia Downturn
The NVDA stock outlook is complex, because there's a correction coming, and you don't want to be in it when it does. 
Via InvestorPlace
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.